Vornorexant
http://dbpedia.org/resource/Vornorexant an entity of type: Thing
Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin OX1 and OX2 receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical.
rdf:langString
rdf:langString
Vornorexant
xsd:integer
68542699
xsd:integer
1084240433
xsd:integer
23
xsd:integer
2265899
xsd:integer
61751857
<second>
-11880.0
xsd:integer
1
xsd:integer
22
rdf:langString
[-2-[[3-pyrazol-1-yl]methyl]-1,3-oxazinan-3-yl]-[5-methyl-2-phenyl]methanone
xsd:integer
7
xsd:integer
2
xsd:integer
137419776
rdf:langString
CC1=CCCN3CCCO[C@H]3CN4C=CCC5=NC=CF
xsd:integer
1
rdf:langString
AEZZJXJIJFSUEM-QFIPXVFZSA-N
rdf:langString
ORN-0829; TS-142
rdf:langString
ZY54BP1CK3
xsd:integer
250
rdf:langString
Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin OX1 and OX2 receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical. Vornorexant has a time to peak of 2.5 hours and a relatively short elimination half-life of 1.3 to 3.3 hours. It was designed to have a short half-life and duration in order to reduce next-day side effects like somnolence.
xsd:nonNegativeInteger
5950
xsd:string
2265899-49-6
xsd:string
ZY54BP1CK3
xsd:string
137419776